Campath (ILEX Pharmaceuticals LP)
- Campath (ILEX Pharmaceuticals LP) – general information
- Pharmacology of Campath (ILEX Pharmaceuticals LP)
- Campath (ILEX Pharmaceuticals LP) for patients
- Campath (ILEX Pharmaceuticals LP) interactions
- Campath (ILEX Pharmaceuticals LP) contraindications
- Additional information about Campath (ILEX Pharmaceuticals LP)
Campath (ILEX Pharmaceuticals LP) - General Information
Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.
Pharmacology of Campath (ILEX Pharmaceuticals LP)
Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations.
Campath (ILEX Pharmaceuticals LP) for patients
Campath (ILEX Pharmaceuticals LP) Interactions
Drug/Laboratory Interactions
No formal drug interaction studies have been performed with Campath. An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies.
Campath (ILEX Pharmaceuticals LP) Contraindications
Campath is contraindicated in patients who have active systemic infections, underlying immunodeficiency (e.g.,seropositive for HIV),or known Type I hypersensitivity or anaphylactic reactions to Campath or to any one of its components.
Additional information about Campath (ILEX Pharmaceuticals LP)
Campath (ILEX Pharmaceuticals LP) Indication: For treatment of B-cell chronic lymphocytic leukemia
Mechanism Of Action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Alemtuzumab
Synonyms: Not Available
Drug Category: Antineoplastic Agents
Drug Type: Biotech; Approved; Investigational
Other Brand Names containing Alemtuzumab: Campath (ILEX Pharmaceuticals LP);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system when bound to B or T lymphocytes
Half Life: ~288 hrs
Dosage Forms of Campath (ILEX Pharmaceuticals LP): Solution Intravenous
Chemical IUPAC Name: Humanized anti-CD52 antibody
Chemical Formula: C6468H10066N1732O2005S40
Alemtuzumab on Wikipedia: https://en.wikipedia.org/wiki/Alemtuzumab
Organisms Affected: Not Available